The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients
Open accessAbstract
The benefit of cytoreductive surgery for glioblastoma multiforme (GBM) is unclear, and selection bias in past series has been observed. The 5-aminolevulinic acid (ALA) study investigated the influence of fluorescence-guided resections on outcome and generated an extensive database of GBM patients with optimized resections. We evaluated whether the Radiation Therapy Oncology Group recursive partitioning analysis (RTOG-RPA) would predict survival of these patients and whether there was any benefit from extensive resections depending on RPA class. A total of 243 per-protocol patients with newly diagnosed GBM were operated on with or without ALA and treated by radiotherapy. Postoperative MRI was obtained in all patients. Patients were allocated into RTOG-RPA classes III-V based on age, KPS, neurological condition, and mental status (as derived from the NIH Stroke Scale). Median overall survival among RPA classes III, IV, and V was 17.8, 14.7, and 10.7 months, respectively, with 2-year survival rates of 26%, 12%, and 7% (p = 0.0007). Stratified for degree of resection, survival of patients with complete resections was clearly longer in RPA classes IV and V (17.7 months vs. 12.9 months, p = 0.0015, and 13.7 months vs. 10.4 months, p = 0.0398; 2-year rates: 21.0% vs. 4.4% and 11.1% vs. 2.6%, respectively), but was not in the small subgroup of RPA class III patients (19.3 vs. 16.3 months, p = 0.14). Survival of patients from the ALA study is correctly predicted by the RTOG-RPA classes. Differences in survival depending on resection status, especially in RPA classes IV and V, support a causal influence of resection on survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423
Self-citationLacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., et al. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,091
Curran, W. J., Scott, C. B., Horton, J., Nelson, J. S., Weinstein, A. S., Fischbach, A. J., Chang, C. H., Rotman, M., Asbell, S. O., Krisch, R. E., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.9.704 · Cited by 1,310
Stummer, W., Reulen, H.-J., Meinel, T., Pichlmeier, U., Schumacher, W., Tonn, J.-C., Rohde, V., Oppel, F., Turowski, B., Woiciechowsky, C., et al. (2008) · Neurosurgery · doi:10.1227/01.neu.0000317304.31579.17 · Cited by 1,035
Self-citationInterrater Reliability of the NIH Stroke Scale
Goldstein, L. B., Bertels, C., & Davis, J. N. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520420080026 · Cited by 986
Stupp, R., Dietrich, P.-Y., Ostermann, S., Pica, A., Maillard, I. P., Maeder, P., Meuli, R. A., Janzer, R. C., Pizzolato, G., Miralbell, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1375 · Cited by 856
Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis
Lamborn, K. R., Chang, S. M., & Prados, M. D. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000620 · Cited by 546
Simpson, J. R., Horton, J., Scott, C., Curran, W. J., Rubin, P., Fischbach, J., Isaacson, S., Rotman, M., Asbell, S. O., Nelson, J. S., et al. (1993) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(93)90203-8 · Cited by 535
Mirimanoff, R.-O., Gorlia, T., Mason, W., Van den Bent, M. J., Kortmann, R.-D., Fisher, B., Reni, M., Brandes, A. A., Curschmann, J., Villa, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5963 · Cited by 509
Cited by
Brown, T. J., Brennan, M. C., Li, M., Church, E. W., Brandmeir, N. J., Rakszawski, K. L., Patel, A. S., Rizk, E. B., Suki, D., Sawaya, R., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1373 · Cited by 1,081
Senft, C., Bink, A., Franz, K., Vatter, H., Gasser, T., & Seifert, V. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70196-6 · Cited by 826
Self-citationGlioblastoma multiforme: State of the art and future therapeutics
Harter, D., Wilson, T., & Karajannis, M. (2014) · Surgical Neurology International · doi:10.4103/2152-7806.132138 · Cited by 327
Recent Advances in Therapy for Glioblastoma
Clarke, J., Butowski, N., & Chang, S. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.5 · Cited by 283
Stummer, W., Tonn, J.-C., Goetz, C., Ullrich, W., Stepp, H., Bink, A., Pietsch, T., & Pichlmeier, U. (2014) · Neurosurgery · doi:10.1227/neu.0000000000000267 · Cited by 277
Self-citation
Metadata
- Authors
- Pichlmeier, U., Bink, A., Schackert, G., & Stummer, W.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-12-01
- Volume
- 10
- Issue
- 6
- Pages
- 1025-1034
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2109172505
- Cited by
- 326
- References
- 21
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients. https://app.cochat.ai/papers/10.1215/15228517-2008-052
- The paper
- Pichlmeier, U., Bink, A., Schackert, G., & Stummer, W. (2008). Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients. Neuro-Oncology. https://doi.org/10.1215/15228517-2008-052
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.